AnGes, Inc. (TYO:4563)

Market Cap	22.24B
Revenue (ttm)	643.00M
Net Income (ttm)	-28.13B
Shares Out	327.07M
EPS (ttm)	-119.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,801,700
Average Volume	5,178,750
Open	70.00
Previous Close	70.00
Day's Range	67.00 - 70.00
52-Week Range	43.00 - 98.00
Beta	1.50
RSI	54.05
Earnings Date	May 9, 2025

About AnGes

AnGes, Inc. engages in the research and development of gene-based medical products. It develops HGF gene therapy product for the treatment of ischemic diseases; NF-κB Decoy Oligo DNA for chronic discogenic lumber back pain; and DNA vaccines for the treatment of hypertension and cervical intraepithelial neoplasia, as well as intranasal formulation of the COVID-19 vaccine. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 55
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4563

Financial Performance

In 2024, AnGes's revenue was 643.00 million, an increase of 323.03% compared to the previous year's 152.00 million. Losses were -28.13 billion, 278.2% more than in 2023.